All In Biotech

Drug Trial Radar · NCT07357415

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jan 24, 2026

Primary completion

Oct 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Conditions

  • Obesity
  • Overweight

Interventions

  • RetatrutideDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: Baseline, Week 104

Locations

35 sites in 3 countries. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Care Access - Huntington Beach

    Huntington Beach, California

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California

  • New Horizon Research Center

    Miami, Florida

  • Encore Medical Research - Weston

    Weston, Florida

  • Pacific Diabetes & Endocrine Center

    Honolulu, Hawaii

  • Monroe Biomedical Research - Louisville

    Louisville, Kentucky

  • Brigham and Women's Hospital Diabetes Program

    Boston, Massachusetts

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • NYC Research INC

    Long Island City, New York

  • Weill Cornell Medical College

    New York, New York

  • Care Access - Raleigh

    Raleigh, North Carolina

  • New Phase Research and Development

    Knoxville, Tennessee

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Cedar Health Research - Texas Native Health

    Dallas, Texas

  • Cedar Health Research

    Dallas, Texas

  • Cedar Health Research - Fort Worth

    Fort Worth, Texas

  • Advanced Research Institute

    Ogden, Utah

  • Dominion Medical Associates, Inc.

    Richmond, Virginia

  • CAMC Institute for Academic Medicine

    Charleston, West Virginia

  • Cicemo Srl

    Buenos Aires, Argentina

  • CARDIAMET Investigaciones Médicas

    Buenos Aires, Argentina

  • Stat Research S.A.

    Buenos Aires, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, Argentina

  • Centro Médico Viamonte

    Buenos Aires, Argentina

  • Aggarwal and Associates Limited

    Brampton, Canada

  • Med Trust Research

    Courtice, Canada

  • Winterberry Research Inc.

    Hamilton, Canada

  • Diex Recherche Inc. Division Joliette

    Joliette, Canada

  • Milestone Research Inc.

    London, Canada

  • Diex Recherche Inc. Division Quebec

    Québec, Canada

  • Diex Recherche Inc. Division Sherbrooke

    Sherbrooke, Canada

  • Canadian Phase Onward

    Toronto, Canada

  • Dr. Anil K. Gupta Medicine Professional Corporation

    Toronto, Canada

  • C.I.C. Mauricie inc.

    Trois-Rivières, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.